Cell death by apoptosis represents a fundamental cellular program that is critically involved in the regulation of various physiological processes.^[@bib1]^ Human cancers are characterized by their inability to properly respond to apoptotic stimuli, as apoptosis is typically impaired during tumorigenesis.^[@bib2]^ As implied by their name, membrane-bound death receptors of the tumor necrosis factor (TNF) receptor 1 (TNFR1) superfamily represent prototypic entry points for external signals to initiate apoptosis and can also sense intracellular cues.^[@bib3]^ In the death receptor (extrinsic) pathway, the binding of death receptors such as TNF-related apoptosis-inducing ligand receptors (TRAIL receptors) by their natural ligands or agonistic antibodies leads to activation of caspase-8 in a receptor-associated death-inducing signaling complex (DISC) that mediates apoptosis by cleaving and activating downstream effector caspases such as caspase-3.^[@bib3]^ Furthermore, internalization of ligand-bound death receptors can subsequently lead to the assembly of a multimeric cell death complex in the cytosol known as complex II that contains receptor-interacting protein 1 (RIP1), FAS-associated via death domain (FADD) and caspase-8.^[@bib4]^

Apoptosis pathways are tightly regulated by pro- and antiapoptotic proteins.^[@bib2]^ For example, 'Inhibitor of Apoptosis\' (IAP) proteins represent a family of antiapoptotic proteins with highly expressed levels in many human cancers.^[@bib5]^ X-linked inhibitor of apoptosis protein (XIAP) inhibits caspase activation by binding caspase-9 and -3/-7 via its baculovirus IAP repeat (BIR) domains.^[@bib6]^ IAP proteins harboring a RING (really interesting new gene) domain, for example, cellular inhibitor of apoptosis (cIAP)1 and cIAP2, can act as E3 ubiquitin ligases and mediate auto- and heteroubiquitination and subsequent proteasomal degradation.^[@bib5]^ IAP proteins are known as key regulators of canonical and non-canonical nuclear factor-*κ*B (NF-*κ*B) pathways.^[@bib5]^ In the canonical NF-*κ*B pathway, I*κ*B*α* gets phosphorylated and degraded upon TNFR1 activation, leading to p65/p50 nuclear translocation and transcriptional activation of NF-*κ*B target genes.^[@bib7]^ cIAP proteins promote activation of the canonical NF-*κ*B pathway by non-degradative ubiquitination of the serine/threonine kinase RIP1.^[@bib8],\ [@bib9]^ In the non-canonical NF-*κ*B pathway, cIAP proteins constitutively stimulate proteasomal degradation of NF-*κ*B-inducing kinase (NIK) in a multiprotein complex together with TNF receptor-associated factor 2 (TRAF2) and TRAF3, thereby preventing proteolytic processing of p100 to p52 and nuclear translocation of p52.^[@bib10],\ [@bib11]^

IAP proteins are held in check by endogenous antagonists including second mitochondria-derived activator of caspase (Smac).^[@bib5]^ Upon its release from the mitochondria into the cytosol, Smac triggers caspase-3 activation by neutralizing XIAP.^[@bib5]^ Small-molecule pharmacological inhibitors of IAP proteins such as Smac mimetic have been developed that antagonize XIAP and also stimulate E3 ligase activity of IAP proteins with a RING domain such as cIAP1/2 and XIAP, leading to their autoubiquitination and proteasomal degradation.^[@bib12],\ [@bib13],\ [@bib14]^ Depletion of cIAP1/2 by Smac mimetic favors deubiquitination of RIP1 that, in turn, facilitates TNF*α*-induced cell death by enhancing the formation of complex II in the cytosol that contains RIP1/FADD/caspase-8.^[@bib8],\ [@bib9]^ In addition, downregulation of cIAP1/2 leads to activation of NF-*κ*B signaling via accumulation of NIK that, in turn, initiates a TNF*α*/TNFR1 autocrine/paracrine loop that has been reported to mediate Smac mimetic-induced cytotoxicity.^[@bib12],\ [@bib13]^ Accordingly, sensitivity of cancer cells to Smac mimetic has been linked to their ability to activate TNF*α*/TNFR1 autocrine/paracrine signaling. However, little is yet known about the molecular determinants that are critical for sensitivity of cancer cells to Smac mimetic. Therefore, in this study we aimed to identify novel regulators of Smac mimetic-induced apoptosis.

Results
=======

TNF*α*/TNFR1 signaling is largely dispensable for BV6-mediated apoptosis in A172 glioblastoma cells
---------------------------------------------------------------------------------------------------

To elucidate the molecular mechanisms of BV6-induced cell death, we analyzed the effects of BV6 in cell lines of different cancer entities. Treatment with BV6 resulted in a dose-dependent reduction of cell viability in A172 glioblastoma cells, MDA-MB-231 breast carcinoma cells, SK-N-AS neuroblastoma cells and Kym-1 rhabdomyosarcoma cells ([Figure 1a](#fig1){ref-type="fig"} and [Supplementary Figure 1a](#sup1){ref-type="supplementary-material"}). In addition, BV6 triggered DNA fragmentation, a biochemical hallmark of apoptosis, in a concentration-dependent manner ([Figure 1b](#fig1){ref-type="fig"} and [Supplementary Figure 1b](#sup1){ref-type="supplementary-material"}), demonstrating that BV6 induces apoptotic cell death. Furthermore, the broad-range caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethylketone (zVAD.fmk) significantly reduced BV6-induced loss of cell viability as well as DNA fragmentation ([Figures 1a and b](#fig1){ref-type="fig"}), in line with caspase-dependent apoptosis.

As a TNF*α*-driven autocrine/paracrine loop that is initiated upon depletion of cIAP proteins has been implicated to mediate Smac mimetic-induced cell death,^[@bib12],\ [@bib13],\ [@bib14]^ we next explored the involvement of TNF*α*/TNFR1 signaling. To this end, we pharmacologically interfered with TNF*α*/TNFR1 signaling by using the TNF*α*-blocking antibody Enbrel. Unexpectedly, Enbrel largely failed to rescue BV6-induced cell death in A172 cells, as it did not prevent BV6-triggered reduction of cell viability and DNA fragmentation ([Figures 1a and b](#fig1){ref-type="fig"} and [Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). In contrast, Enbrel significantly inhibited BV6-induced loss of cell viability and DNA fragmentation in MDA-MB-231, SK-N-AS and Kym1 cells ([Figures 1a and b](#fig1){ref-type="fig"}).

In addition to this pharmacological approach, we also employed a genetic strategy to block TNF*α*/TNFR1 signaling using RNAi-mediated knockdown of TNFR1. We selected A172 and MDA-MB-231 as prototypic cell lines that were (MDA-MB-231 cells) or were not (A172 cells) protected by Enbrel against BV6-induced apoptosis. Similarly, TNFR1 silencing largely failed to protect against Smac mimetic-induced loss of cell viability and DNA fragmentation in A172 cells ([Figures 1c--e](#fig1){ref-type="fig"}). Control experiments showed that TNFR1 silencing suppressed TNF*α*-stimulated signaling in A172 cells, as assessed by inhibition of I*κ*B*α* phosphorylation ([Supplementary Figure 3](#sup1){ref-type="supplementary-material"}). In contrast, TNFR1 knockdown significantly inhibited Smac mimetic-induced cell death in MDA-MB-231 cells ([Figures 1c--e](#fig1){ref-type="fig"}). These data point to a cell line-dependent requirement of TNF*α*/TNFR1 signaling in Smac mimetic-induced cell death. To further investigate the underlying molecular mechanisms, we used A172 and MDA-MB-231 as prototypic cell lines that undergo apoptosis upon treatment with BV6 in a TNF*α*-independent and TNF*α*-dependent manner, respectively.

Depletion of IAP proteins and activation of caspases by BV6
-----------------------------------------------------------

As Smac mimetic has been shown to stimulate ubiquitination and proteasomal degradation of IAP proteins harboring a RING domain,^[@bib12],\ [@bib13],\ [@bib14]^ we next examined IAP protein levels upon exposure to BV6. Treatment with BV6 caused downregulation of cIAP1 and XIAP in both A172 and MDA-MB-231 cells ([Figure 2a](#fig2){ref-type="fig"}). Furthermore, depletion of cIAP proteins by Smac mimetic has been reported to increase formation of a cytosolic multimeric complex comprising RIP1, FADD and caspase-8, as cIAP proteins can act as E3 ligases for ubiquitination of RIP1.^[@bib12],\ [@bib13],\ [@bib14]^ Indeed, immunoprecipitation of caspase-8 revealed that BV6 stimulated the interaction of RIP1, FADD and caspase-8 in a time-dependent manner ([Figure 2b](#fig2){ref-type="fig"}). As this cytosolic RIP1/FADD/caspase-8-containing complex has been described to drive caspase-8 activation,^[@bib8],\ [@bib9]^ we next monitored activation of the caspase cascade by western blotting. BV6 induced processing of caspase-8, -9 and -3 into active cleavage fragments as indicated by the appearance of caspase-8 cleavage products p43/41 and p18, caspase-9 cleavage fragments p37/p35 and caspase-3 cleavage products p17/12 ([Figure 2c](#fig2){ref-type="fig"}). Cleavage of caspases was accompanied by decreased expression levels of the proenzyme forms of caspase-8, -9 and -3, especially in MDA-MB-231 cells ([Figure 2c](#fig2){ref-type="fig"}), confirming that caspases are activated by proteolytic cleavage.

BV6 activates canonical and non-canonical NF-*κ*B signaling
-----------------------------------------------------------

As Smac mimetic-mediated apoptosis has been reported to engage TNF*α*/TNFR1 signaling by activating NF-*κ*B upon depletion of IAP proteins,^[@bib12],\ [@bib13],\ [@bib14]^ we asked whether the observed differential requirement of TNF*α*/TNFR1 signaling is due to differences in BV6-stimulated NF-*κ*B activation. To assess non-canonical NF-*κ*B activation, we determined accumulation of NIK protein and proteolytic processing of p100 to p52. For canonical NF-*κ*B activation, we analyzed phosphorylation of I*κ*B*α* and p65 as well as degradation of I*κ*B*α*. BV6 caused accumulation of NIK and processing of p100 to p52 in both A172 and MDA-MB-231 cells ([Figure 3a](#fig3){ref-type="fig"}). In addition, BV6 stimulated phosphorylation of p65 and I*κ*B*α* that was accompanied by downregulation of I*κ*B*α* protein levels in both A172 and MDA-MB-231 cells ([Figure 3a](#fig3){ref-type="fig"}). As positive control for canonical NF-*κ*B signaling, we used TNF*α* that potently stimulated phosphorylation and degradation of I*κ*B*α* protein, whereas it did not cause NIK accumulation or p100 processing ([Figure 3a](#fig3){ref-type="fig"}). The more pronounced degradation of I*κ*Ba in TNF*α*- *versus* BV6-treated cells may be due to stronger and more rapid NF-*κ*B activation by TNF*α*.

To analyze which NF-*κ*B subunits translocate into the nucleus, we prepared cytosolic and nuclear extracts. BV6 stimulated nuclear translocation of p52, p50, RelB and phospho-p65 in both A172 and MDA-MB-231 cells ([Figure 3b](#fig3){ref-type="fig"}). Furthermore, analysis of DNA-binding by EMSA showed that BV6 increased NF-*κ*B DNA binding ([Supplementary Figure 4](#sup1){ref-type="supplementary-material"}). To determine whether NF-*κ*B DNA binding leads to transcriptional activation of NF-*κ*B target genes, we examined both NF-*κ*B transcriptional activity utilizing a NF-*κ*B-driven reporter construct and NF-*κ*B target gene expression using reverse transcriptase quantitative PCR (RT-qPCR) analysis. BV6 significantly increased NF-*κ*B transcriptional activity ([Figure 3c](#fig3){ref-type="fig"}) and upregulated prototypic NF-*κ*B target genes including *TNFα*, *RelB* and *p100* in both A172 and MDA-MB-231 cells ([Figure 3d](#fig3){ref-type="fig"}). These experiments showed that BV6 activates canonical and non-canonical NF-*κ*B signaling in A172 and MDA-MB-231 cells.

NF-*κ*B is necessary for BV6-induced cell death
-----------------------------------------------

We next asked whether NF-*κ*B activation is required for BV6-induced cell death. To block NF-*κ*B activation we overexpressed I*κ*B*α* superrepressor (I*κ*B*α*-SR) ([Figure 4a](#fig4){ref-type="fig"}). Control experiments showed that I*κ*B*α* overexpression suppressed BV6-stimulated phosphorylation of I*κ*B*α* and protein levels of NF-*κ*B target genes such as *IκBα*, *p100* and *RelB* ([Figure 4b](#fig4){ref-type="fig"}). In addition, I*κ*B*α*-SR inhibited NF-*κ*B DNA binding and reduced mRNA levels of NF-*κ*B target genes, that is, *TNFα*, *p100* and *RelB* ([Supplementary Figure 5](#sup1){ref-type="supplementary-material"}), indicating that I*κ*B*α*-SR suppresses both canonical and non-canonical NF-*κ*B signaling. Importantly, inhibition of NF-*κ*B by I*κ*B*α*-SR significantly reduced BV6-stimulated loss of cell viability and DNA fragmentation compared with vector control cells in both A172 and MDA-MB-231 cells ([Figures 4c and d](#fig4){ref-type="fig"}). In addition, I*κ*B*α*-SR overexpression profoundly inhibited caspase activation and attenuated the formation of the RIP1/FADD/caspase-8 cytosolic cell death complex upon treatment with BV6 compared with vector control cells ([Figures 4e and f](#fig4){ref-type="fig"}). Together, this set of experiments demonstrates that NF-*κ*B is required for BV6-stimulated cell death in A172 and MDA-MB-231 cells.

Identification of DR5 as an NF-*κ*B target gene that is upregulated by BV6
--------------------------------------------------------------------------

As in this study TNF*α* turned out to be largely dispensable for BV6-induced cell death in A172 cells despite the requirement of NF-*κ*B, we next aimed to identify NF-*κ*B target genes other than *TNFα* that act as critical mediators of BV6-induced apoptosis. To this end, we performed a genome-wide cDNA microarray analysis and compared BV6-stimulated gene expression in A172 cells overexpressing I*κ*B*α*-SR with vector control cells. Gene set enrichment analysis (GSEA) verified strong enrichment of NF-*κ*B target genes under treated NF-*κ*B-proficient conditions, proving functionality of I*κ*B*α*-SR expression ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). It is noteworthy that *LRIG1*, which has already been described in the context of transcriptional regulation by Smac mimetic,^[@bib15]^ was displayed among the top hits and has been validated to be regulated by BV6 treatment in a NF-*κ*B-dependent manner ([Supplementary Figure 6](#sup1){ref-type="supplementary-material"}). Interestingly, by this approach we identified *death receptor 5 (DR5)*, another death receptor of the TNFR superfamily, as one of the top listed NF-*κ*B-regulated genes that is differentially upregulated upon treatment with BV6 in A172 vector control compared with I*κ*B*α*-SR-overexpressing cells. Validation experiments using RT-qPCR and western blot analysis confirmed that treatment with BV6 triggered upregulation of DR5 mRNA and protein expression ([Figures 5a and b](#fig5){ref-type="fig"}). To ensure that DR5 is regulated in a NF-*κ*B-dependent manner, we compared DR5 expression in I*κ*B*α*-SR-overexpressing A172 cells with vector control cells. It is noteworthy that I*κ*B*α*-SR overexpression prevented the BV6-stimulated increase in DR5 mRNA and protein expression ([Figures 5c and d](#fig5){ref-type="fig"}). In addition, constitutive expression of DR5 mRNA and protein was reduced in I*κ*B*α*-SR-overexpressing cells compared with vector control cells ([Figures 5c and d](#fig5){ref-type="fig"}). These findings demonstrate that BV6 triggers upregulation of DR5 in a NF-*κ*B-dependent manner.

DR5 upregulation is critically required for BV6-mediated cell death
-------------------------------------------------------------------

To investigate whether BV6-stimulated upregulation of DR5 is necessary for BV6-mediated cell death, we knocked down DR5 by siRNA. Control experiments confirmed that two distinct siRNA sequences targeting DR5 profoundly suppressed constitutive expression and BV6-stimulated upregulation of DR5 mRNA and protein ([Figures 6a and b](#fig6){ref-type="fig"}). Importantly, knockdown of DR5 strongly inhibited BV6-triggered loss of viability and DNA fragmentation ([Figures 6c and d](#fig6){ref-type="fig"}). In addition, the BV6-induced cleavage of caspase-8, -9 and -3 into active fragments and formation of the RIP1/FADD/caspase-8 complex was severely impaired in DR5 knockdown cells compared with control cells ([Figures 6e and f](#fig6){ref-type="fig"}). Interestingly, the caspase-8 cleavage products p43 and p41 were detected upon BV6 treatment within the cytosolic RIP1/FADD/caspase-8 complex in control cells, but not in DR5 knockdown cells ([Figure 6f](#fig6){ref-type="fig"}), underlining that DR5-mediated formation of this complex is required to drive caspase-8 activation.

In a second genetic approach to block DR5, we used three distinct short-hairpin RNA (shRNA) vectors that prevented in particular the BV6-stimulated DR5 upregulation rather than constitutive expression of DR5 ([Supplementary Figure 7a](#sup1){ref-type="supplementary-material"}). Abrogation of BV6-mediated upregulation of DR5 significantly inhibited BV6-induced loss of viability and DNA fragmentation in DR5 knockdown cells compared with control cells ([Supplementary Figures 7b and c](#sup1){ref-type="supplementary-material"}). Together, these independent approaches to block DR5 demonstrate that DR5 is necessary for BV6-mediated formation of the RIP1/FADD/caspase-8 complex, caspase activation and cell death in A172 cells. In comparison, silencing of DR5 failed to rescue MDA-MB-231 cells from BV6-induced apoptosis, although BV6 triggered a modest increase of DR5 mRNA and protein levels in these cells ([Supplementary Figures 8a--d](#sup1){ref-type="supplementary-material"}). Control experiments showed that DR5 silencing suppressed ETR2-induced cell death in MDA-MB-231 cells, verifying a functional knockdown ([Supplementary Figure 8e](#sup1){ref-type="supplementary-material"}).

As *TRAIL* is known as another NF-*κ*B target gene, we explored the possibility that TRAIL is involved in mediating BV6-induced apoptosis. BV6 slightly increased TRAIL mRNA expression in a time-dependent manner ([Supplementary Figure 9a](#sup1){ref-type="supplementary-material"}). The addition of a TRAIL-blocking antibody failed to protect against BV6-triggered loss of viability under conditions where it fully prevented TRAIL-induced cell death ([Supplementary Figure 9b](#sup1){ref-type="supplementary-material"}). In comparison, genetic silencing of TRAIL provided some protection against BV6-induced loss of viability at low doses of BV6 ([Supplementary Figures 9c and d](#sup1){ref-type="supplementary-material"}). These results suggest that TRAIL may directly bind to DR5 as transmembrane protein and is therefore spared from the inhibitory actions of the TRAIL-blocking antibody. Together, this set of experiments indicates that BV6-induced apoptosis in A172 cells is mediated via DR5 in a partially TRAIL-dependent manner.

Discussion
==========

Smac mimetic is considered as a promising cancer therapeutic to initiate cell death in cancer cells. Although an autocrine/paracrine TNF*α* loop has been implicated to mediate Smac mimetic-induced cell death, little is yet known about additional factors that determine sensitivity of cancer cells to Smac mimetic-triggered apoptosis. Using an unbiased genome-wide gene expression profiling approach, we identify DR5 as a novel key mediator of Smac mimetic-induced apoptosis. Several lines of evidence support this conclusion ([Figure 7](#fig7){ref-type="fig"}). First, BV6-triggered increase in DR5 mRNA and protein expression is critically required for BV6-induced apoptosis, as knockdown of DR5 using transient and stable strategies for gene silencing strongly reduces apoptosis by BV6. DR5 initiates apoptosis by promoting the formation of a RIP1/FADD/caspase-8 cell death complex in the cytosol that drives activation of caspase-8, -9 and -3 and apoptosis, as all these events are inhibited by DR5 silencing. DR5 mediates BV6-induced apoptosis in a soluble ligand-independent manner, as a TRAIL-blocking antibody fails to rescue BV6-induced apoptosis under conditions where it blocks TRAIL-induced cell death. Second, TNF*α*/TNFR1 signaling is largely dispensable for BV6-induced apoptosis in a cell type-dependent manner, as pharmacological or genetic inhibition of the TNF*α*/TNFR1 ligand/receptor system affords little protection of A172 glioblastoma cells against BV6-induced apoptosis. Third, BV6 stimulates DR5 expression in a NF-*κ*B-dependent manner, as inhibition of NF-*κ*B by overexpression of dominant-negative I*κ*B*α*-SR abolishes DR5 upregulation by BV6. Together, these findings demonstrate that -- besides an autocrine/paracrine TNF*α*/TNFR1 loop -- BV6-stimulated activation of DR5 can serve as an entry site to engage the apoptotic machinery upon treatment with BV6.

The novelty of our study particularly resides in the discovery of DR5 as a key mediator of Smac mimetic-induced apoptosis. So far, upregulation of DR5 in response to treatment with Smac mimetic has not yet been reported. DR5 is known as a NF-*κ*B target gene that harbors a NF-*κ*B consensus binding site within its first intronic region.^[@bib16],\ [@bib17],\ [@bib18]^ Consistently, we found that BV6 increases DR5 mRNA and protein expression in a NF-*κ*B-dependent manner. DR5 is required for the formation of a cytosolic cell death complex composed of RIP1, FADD and caspase-8 upon treatment with BV6 that drives caspase-8 activation. In support of this notion, knockdown of DR5 abolishes cleavage of caspase-8 within the cytosolic RIP1/FADD/caspase-8 complex. It is interesting to note that this RIP1/FADD/ caspase-8-containing cytosolic complex has been reported to assemble upon treatment with Smac mimetic in a TNF*α*-dependent manner.^[@bib12],\ [@bib13],\ [@bib19]^ This indicates that Smac mimetic activates death receptor/ligands systems, that is, TNF*α*/TNFR1 or DR5, via NF-*κ*B in a context-dependent manner, which in turn promote the assembly of the RIP1/FADD/caspase-8-containing complex in the cytosol that drives caspase-8 activation and apoptosis.

Our study indicates that DR5 mediates BV6-induced apoptosis in a partially TRAIL-dependent manner independently of the soluble form of the ligand, as genetic silencing of TRAIL partially rescues cell death at low concentrations of BV6, whereas pharmacological inhibition of TRAIL fails to protect against BV6-induced apoptosis. Although previous studies investigated the contribution of the ligand TRAIL to Smac mimetic-induced apoptosis and demonstrated that knockdown of TRAIL, TRAIL-blocking antibodies or TRAIL receptor decoy constructs that sequester TRAIL were all unable to afford protection against Smac mimetic-induced apoptosis,^[@bib12],\ [@bib13],\ [@bib19]^ our present study particularly addressed the role of TRAIL receptors. Of the two proapoptotic TRAIL receptors, DR5 is especially relevant for glioblastoma, as DR4 is frequently epigenetically silenced in this tumor.^[@bib20]^

Previously, sensitivity to Smac mimetic has been linked to activation of TNF*α*/TNFR1, another ligand/receptor system of the death receptor family. Accordingly, Smac mimetic-triggered depletion of cIAP proteins was shown to initiate a TNF*α*/TNFR1 autocrine/paracrine loop via NIK accumulation and NF-*κ*B activation.^[@bib12],\ [@bib13]^ Consistent with these reports,^[@bib12],\ [@bib13]^ we found that several BV6-sensitive cell lines die via a TNF*α*/TNFR1 autocrine/paracrine signaling. However, our study highlights the fact that TNF*α*/TNFR1 is not the only death receptor ligand/receptor system that can mediate Smac mimetic-induced apoptosis, as the TNF*α*-blocking antibody Enbrel or TNFR1 knockdown largely fail to rescue BV6-induced apoptosis in A172 glioblastoma cells. It is noteworthy that we demonstrate that upregulation of DR5 can represent an additional mechanism besides TNF*α*/TNFR1 that is critical for Smac mimetic-triggered apoptosis. Independently of our study, there is very recent evidence of TNF*α*-independent, Smac mimetic-induced apoptosis in breast cancer cells, as neutralizing antibodies against TNF*α* or TNFR1 knockdown failed to reverse cell death.^[@bib21]^ However, the molecular mechanisms of cell death induction by Smac mimetic were not identified in that study,^[@bib21]^ underscoring the novelty of our present report.

Irrespectively of the differential requirement of TNF*α*/TNFR1 or DR5 signaling, our findings demonstrate that BV6-stimulated NF-*κ*B activation is critically required for apoptosis induction, as inhibition of NF-*κ*B blocks Smac mimetic-triggered apoptosis. These findings support a model according to which Smac mimetic, via depletion of IAP proteins, activates NF-*κ*B that, in turn, engages NF-*κ*B-dependent proapoptotic signaling pathways in a context-dependent manner via TNF*α*/TNFR1 or DR5 signaling. In addition, additional NF-*κ*B-dependent, yet undefined, mechanisms may be involved.

Although Smac mimetic has been described to trigger NF-*κ*B activation, the functional relevance of NF-*κ*B as a pro- or antiapoptotic factor during Smac mimetic-induced apoptosis has been controversially discussed. On one side, activation of NF-*κ*B was shown to be required for Smac mimetic-induced apoptosis, as inhibition of NF-*κ*B abrogated Smac mimetic-induced apoptosis.^[@bib22],\ [@bib23],\ [@bib24],\ [@bib25]^ On the other side, an antiapoptotic function was ascribed to NF-*κ*B, as blockage of NF-*κ*B resulted in enhanced apoptosis upon treatment with Smac mimetic.^[@bib26],\ [@bib27]^ These differences may be explained by the context-dependent role of NF-*κ*B in the regulation of apoptosis, as there is an increasing number of studies in recent years showing that NF-*κ*B can exert a proapoptotic function under certain circumstances in a cell type- and/or stimulus-dependent manner in addition to its well-described antiapoptotic properties.^[@bib28],\ [@bib29],\ [@bib30]^

Our present study provides further insights into the regulation of NF-*κ*B signaling by Smac mimetic. Detailed analysis reveals activation of both canonical and non-canonical NF-*κ*B pathways by BV6. This might be mediated through crosstalk between the two NF-*κ*B signaling branches: NIK, a well-described mediator of non-canonical NF-*κ*B signaling, accumulates upon cIAP1/2 depletion by BV6 and initiates p100 processing.^[@bib12],\ [@bib13]^ NIK is known to activate IKK*α* and can mediate crosstalk between the non-canonical and canonical branches of NF-*κ*B signaling, for example, through activation of IKK*β*, the main kinase for I*κ*B*α*, resulting in I*κ*B*α* degradation and activation of the canonical NF-*κ*B pathway.^[@bib7]^ Alternatively, Smac mimetic may directly activate canonical NF-*κ*B signaling. Accordingly, the BV6-stimulated increase in the E3 ubiquitin ligase activity of cIAP proteins may trigger an initial wave of heteroubiquitination including ubiquitination of RIP1, leading to activation of the canonical NF-*κ*B pathway. Our data support the first model, that is, activation of both NF-*κ*B signaling branches via crosstalk, as hallmarks of canonical activation, such as I*κ*B*α* phosphorylation, occur in parallel with the peak of NIK accumulation and well after degradation of cIAP1. Furthermore, our data demonstrate that dominant-negative I*κ*B*α*-SR suppresses non-canonical NF-*κ*B signaling via crosstalk mechanisms in addition to its well-known function as an inhibitor of the canonical NF-*κ*B pathway. Accordingly, expression levels of p100 and RelB, the two NF-*κ*B target genes, are suppressed upon I*κ*B*α*-SR overexpression, thereby attenuating non-canonical NF-*κ*B signaling.

By identifying DR5 as a critical mediator of Smac mimetic-induced apoptosis, our findings provide novel insights into the determinants that control susceptibility of cancer cells to Smac mimetic. The relevance of our study is underscored by the fact that small-molecule inhibitors of IAP proteins such as Smac mimetic are presently evaluated in early clinical trials.^[@bib5]^ Thus, a better understanding of the molecular determinants of Smac mimetic-induced apoptosis will be critical for the successful translation of this strategy into clinical application.

Materials and Methods
=====================

Cell culture and chemicals
--------------------------

Cell lines were obtained from ATCC (Manassas, VA, USA) and grown in DMEM medium (Invitrogen, Karlsruhe, Germany) supplemented with 1% penicillin/streptomycin, 1% sodium pyruvate (both from Invitrogen) and 10% fetal calf serum (Invitrogen). BV6, the bivalent Smac mimetic,^[@bib12]^ was kindly provided by Genentech (South San Francisco, CA, USA) and Enbrel by Pfizer (Berlin, Germany). Recombinant human TNF*α* was purchased from Biochrom (Berlin, Germany). All chemicals were obtained from Sigma (Deisenhofen, Germany) unless indicated otherwise.

Transduction and transfection
-----------------------------

Overexpression of the dominant-negative I*κ*B*α*-SR was performed by retroviral transduction using I*κ*B*α* (S32; 36A) and the pCFG5-IEGZ retroviral vector system as previously described.^[@bib29]^ Knockdown of DR5 was performed by lentiviral shRNA vectors as previously described.^[@bib31]^ Shortly, HEK293T cells were transfected with 7.5 *μ*g pGIPZ-shRNAmir vector, using calcium phosphate transfection. All pGIPZ-shRNAmir-vectors were purchased from Thermo Fisher Scientific (Dreieich, Germany): non-silencing control (Ctrl): RHS4346, shDR5_1 shRNA: RHS4430-99157936, shDR5_2 shRNA: RHS4430-101030035, shDR5_3 shRNA: RHS4430-101035311. Virus-containing supernatant was collected, filtered and used for spin transduction at 30°C in the presence of 8 *μ*g/ml polybrene. Transduced cells were selected with 1 *μ*g/ml puromycin (Sigma). For transient knockdown by siRNA, cells were reversely transfected with 5 nM SilencerSelect siRNA (Invitrogen), control siRNA (4390843) or targeting siRNAs (s16756 and s16758 for DR5, s14265 and s14266 for TNFR1 and s16663 for TRAIL) using Lipofectamine RNAi Max (Invitrogen) and OptiMEM (Life Technologies, Darmstadt, Germany).

Determination of apoptosis and cell viability
---------------------------------------------

Apoptosis was determined by flow cytometric analysis of DNA fragmentation of propidium iodide (PI)-stained nuclei (FACSCanto II, BD Biosciences, Heidelberg, Germany) as described previously.^[@bib32]^ The percentage of specific apoptosis was calculated by subtracting the percentage of spontaneous apoptosis from the percentage of induced apoptosis. Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay according to the manufacturer\'s instructions (Roche Diagnostics, Mannheim, Germany).

Western blotting and immunoprecipitation
----------------------------------------

Western blot analysis was performed as described previously^[@bib33]^ using the following antibodies: anti-cIAP1 (R&D Systems, Inc., Wiesbaden-Nordenstadt, Germany), anti-XIAP from BD Biosciences, anti-caspase-3, anti-NIK and anti-phospho-p65 from Cell Signaling (Beverly, MA, USA), anti-*β*-actin (Sigma), anti-*α*-tubulin (Calbiochem, Darmstadt, Germany), anti-p50, anti-p65, anti-RelB and anti-TNFR1 from Santa Cruz Biotechnology (Santa Cruz, CA, USA), anti-p52 and anti-DR5 (Millipore, Schwalbach, Germany), anti-lamin B1 (Abcam, Cambridge, UK) and anti-GAPDH (BioTrend, Cologne, Germany). Donkey anti-mouse IgG, donkey anti-rabbit IgG or donkey anti-goat IgG labeled with IRDye infrared dyes were used for fluorescence detection at 700 nm 800 nm (LI-COR Biotechnology, Bad Homburg, Germany). Caspases were immunodetected by enhanced chemoluminescence (Amersham Biosciences, Freiburg, Germany) using an anti-rabbit IgG-HRP as secondary antibody. Immunoprecipitation of caspase-8 and analysis of RIP1/FADD/caspase-8 interaction was performed as described previously.^[@bib25]^

NF-*κ*B reporter assay
----------------------

NF-*κ*B transcriptional activity was determined using the NF-*κ*B Reporter System pTRH1-NF-*κ*B-EGFP from System Biosciences (TR503PA-1, Mountain View, CA, USA) according to the manufacturer\'s instructions. Briefly, NF-*κ*B reporter activity was determined by flow cytometric analysis of median FITC intensity of the living cell population.

Quantitative real-time PCR
--------------------------

Total RNA was extracted using peqGOLD Total RNA kit from Peqlab Biotechnologie GmbH (Erlangen, Germany) according to the manufacturer\'s instructions. Total RNA (2 *μ*g) was used to synthetize the corresponding cDNA using RevertAid H Minus First Strand cDNA Synthesis Kit (MBI Fermentas GmbH, St. Leon-Rot, Germany). To quantify gene expression levels, SYBR-Green-based quantitative RT-qPCR was performed using the 7900HT fast real-time PCR system from Applied Biosystems (Darmstadt, Germany). Data were normalized on 28S-rRNA expression as reference gene. Primers are listed in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}. Melting curves were plotted to verify the specificity of the amplified products. All determinations were performed in duplicate. The relative expression of the target gene transcript and reference gene transcript was calculated as ΔΔC~t~. At least two independent experiments were performed for each gene. TRAIL mRNA levels were assessed by TaqMan Gene Expression Assay (Life Technologies, Hs00921974_m1) according to the manufacturer\'s protocol.

Statistical analysis
--------------------

Statistical significance was assessed by two-sided Student\'s *t*-test using Microsoft Excel (Microsoft Deutschland GmbH, Unterschleißheim, Germany); \**P*\<0.05; \*\**P*\<0.01.
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:   baculovirus IAP repeat

cIAP1

:   cellular inhibitor of apoptosis 1
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:   death-inducing signaling complex

DR5

:   death receptor 5

FADD

:   FAS-associated protein with death domain

GSEA

:   gene set enrichment analysis

IAP

:   inhibitor of apoptosis

I*κ*B*α*-SR

:   I*κ*Bα superrepressor

MTT

:   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

NF-*κ*B

:   nuclear factor-*κ*B

PI

:   propidium iodide

RING

:   really interesting new gene

RIP1

:   receptor-interacting protein 1

RT-qPCR

:   reverse transcriptase quantitative PCR

Smac

:   second mitochondria-derived activator of caspase

TNF

:   tumor necrosis factor

TNFR1

:   tumor necrosis factor receptor 1

TRAF

:   TNF receptor-associated factor

TRAIL

:   TNF-related apoptosis-inducing ligand

XIAP

:   X-linked inhibitor of apoptosis protein

zVAD.fmk

:   Z-Val-Ala-Asp (OMe)-fluoromethylketone
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###### 

BV6-mediated apoptosis in A172 cells is mainly TNF*α*-independent. (**a** and **b**) Cells were treated for 72 h with indicated concentrations of BV6 in the presence or absence of 20 *μ*M zVAD.fmk or 10 *μ*g/ml Enbrel. Cell viability was measured by MTT or crystal violet assay and is expressed as the percentage of untreated controls (**a**). Apoptosis was determined by DNA fragmentation of PI-stained nuclei using flow cytometry (**b**). Mean±S.D. of three independent experiments performed in duplicate are shown. (**c**--**e**) Cells were transiently transfected with siRNA against TNFR1 or control siRNA and treated for 72 h with indicated concentrations of BV6. Protein expression of TNFR1 was analyzed by western blotting, and GAPDH served as loading control (**c**). Cell viability was measured by MTT assay and is expressed as the percentage of untreated controls (**d**). Apoptosis was determined by DNA fragmentation of PI-stained nuclei using flow cytometry and the percentage of specific apoptosis is shown (**e**). Mean±S.E.M. of three to four independent experiments performed in duplicate are shown
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![BV6 triggers depletion of IAP proteins and caspase activation. (**a**) A172 and MDA-MB-231 cells were treated for indicated times with 5 *μ*M BV6 (A172) or 50 nM BV6 (MDA-MB-231). Expression levels of cIAP1 and XIAP were analyzed by western blotting. Expression of GAPDH served as loading control. (**b**) A172 cells were treated for indicated times with 5 *μ*M BV6 in the presence of 20 *μ*M zVAD.fmk. Caspase-8 was immunoprecipitated using an anti-caspase-8 antibody and detection of indicated proteins was done by western blotting. (**c**) A172 and MDA-MB-231 cells were treated for indicated times with 5 *μ*M BV6 (A172) or 50 nM BV6 (MDA-MB-231); asterisks indicate unspecific bands. Caspase activation was analyzed by western blotting, and active cleavage fragments are indicated by arrow heads. Expression of *β*-actin and GAPDH served as loading controls](cddis2013457f2){#fig2}

###### 

BV6 activates the canonical and non-canonical NF-*κ*B pathway. (**a**) A172 and MDA-MB-231 cells were treated for indicated times with 5 *μ*M BV6 (A172) or 50 nM BV6 (MDA-MB-231); stimulation with 10 ng/ml TNF*α* was used as prototypic canonical NF-*κ*B stimulus. Expression and/or phosphorylation of NIK, p100, p52, p65 and I*κ*B*α* were analyzed by western blotting. Expression of GAPDH served as loading control. (**b**) A172 and MDA-MB-231 cells were treated for indicated times with 5 *μ*M BV6 (A172) or 50 nM BV6 (MDA-MB-231). Expression levels of p50, p52, p65 and RelB were analyzed in the nucleus or in the cytosol by western blotting. *α*-tubulin served as purity control for cytoplasmic fractions, lamin B1 for nuclear fractions and *β*-actin as loading control for both fractions. (**c**) A172 and MDA-MB-231 cells were treated for 24 h with 5 *μ*M BV6 (A172) or 50 nM BV6 (MDA-MB-231). NF-*κ*B transcriptional activity was determined using a FITC-labeled NF-*κ*B reporter construct. Fold increase in NF-*κ*B transcriptional activity is shown with mean±S.D. of three independent experiments performed in at least triplicate. (**d**) A172 and MDA-MB-231 cells were treated for indicated times with 5 *μ*M BV6 (A172) or 50 nM BV6 (MDA-MB-231). mRNA expression levels of TNF*α*, p100 and RelB were analyzed by RT-qPCR. Fold increase in RNA levels is shown with mean+S.E.M. of two to five independent experiments performed in triplicate
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###### 

NF-*κ*B is required for BV6-induced cell death. (**a**) A172 and MDA-MB-231 cells were transduced with I*κ*B*α*-SR or vector control. Expression of I*κ*B*α* and I*κ*B*α*-SR was analyzed by western blotting. GAPDH expression served as loading control. (**b**) A172 and MDA-MB-231 cells were transduced with I*κ*B*α*-SR or vector control. Cells were treated for indicated times with 5 *μ*M BV6 (A172) or 50 nM BV6 (MDA-MB-231). Expression and/or phosphorylation of cIAP1, p100, p52, RelB and I*κ*B*α* were analyzed by western blotting. Expression of GAPDH served as loading control. (**c** and **d**) A172 and MDA-MB-231 cells stably expressing I*κ*B*α*-SR or vector control were treated for 72 h with indicated concentrations of BV6. Cell viability was measured by MTT or crystal violet assay and is expressed as the percentage of untreated controls (**c**). Apoptosis was determined by DNA fragmentation of PI-stained nuclei using flow cytometry (**d**). Mean±S.D. of three to seven independent experiments performed in duplicate are shown. (**e**) A172 cells stably expressing I*κ*B*α*-SR or vector control were treated for indicated times with 5 *μ*M BV6. Caspase activation was analyzed by western blotting, and active cleavage fragments are indicated by arrow heads; *β*-actin served as loading control; asterisks indicate unspecific bands. (**f**) A172 cells were treated for 24 h with 5 *μ*M BV6 in the presence of 20 *μ*M zVAD.fmk. Caspase-8 was immunoprecipitated using an anti-caspase-8 antibody and detection of indicated proteins was done by western blotting
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![BV6 stimulates upregulation of DR5 via NF-*κ*B. (**a** and **b**) A172 cells were treated for indicated times with 5 *μ*M BV6. DR5 mRNA levels were analyzed by RT-qPCR and fold increase in DR5 mRNA levels is shown (**a**). Mean±S.E.M. values of three independent experiments are shown. DR5 protein expression was analyzed by western blotting; *β*-actin served as loading control (**b**). (**c** and **d**) A172 cells stably expressing I*κ*B*α*-SR or vector control were treated for indicated times with 5 *μ*M BV6. DR5 mRNA levels were analyzed by RT-qPCR and fold increase in DR5 mRNA levels is shown (**c**). Mean±S.D. values of five independent experiments are shown. DR5 protein expression was analyzed by western blotting; *β*-actin served as loading control (**d**)](cddis2013457f5){#fig5}

![DR5 upregulation is necessary for BV6-mediated cell death. A172 cells were transiently transfected with 5 nM siRNA targeting DR5 or control siRNA and treated for 6 h (RT-qPCR) or 24 h (western blotting) with 5 *μ*M BV6. Protein expression of DR5 was analyzed by western blotting, and GAPDH served as loading control (**a**). DR5 mRNA levels were analyzed by RT-qPCR and fold increase in DR5 mRNA levels is shown (**b**). Mean±S.D. values of two independent experiments are shown. Cell viability was measured by MTT assay and is expressed as the percentage of untreated controls (**c**). Apoptosis was determined by DNA fragmentation of PI-stained nuclei using flow cytometry and the percentage of specific apoptosis is shown (**d**). Mean±S.D. of three to four independent experiments performed in duplicate are shown. Caspase activation was analyzed by western blotting, active cleavage fragments are indicated by arrow heads; *β*-actin served as loading control; asterisks indicate unspecific bands (**e**). Caspase-8 was immunoprecipitated using an anti-caspase-8 antibody and detection of indicated proteins was done by western blotting (**f**)](cddis2013457f6){#fig6}

![Scheme of BV6-induced signaling pathways. BV6 triggers NF-*κ*B activation and induction of target genes such as *TNFα* or *DR5*. NF-*κ*B mediates BV6-induced apoptosis in a TNF*α*-dependent manner via an autocrine/paracrine TNF*α*/TNFR1 loop or, alternatively, in a DR5-dependent manner. BV6-stimulated, NF-*κ*B-dependent upregulation of DR5 is required for the formation of a cytosolic complex consisting of caspase-8, RIP1 and FADD, subsequent caspase activation and apoptosis](cddis2013457f7){#fig7}
